ProQR Therapeutics (PRQR) Gains from Investment Securities (2020 - 2026)

ProQR Therapeutics has reported Gains from Investment Securities for 7 years, with the latest figure at -$63220.3 in Q1 2026.

• Quarterly Gains from Investment Securities rose 78.69% year-over-year to -$63220.3 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$239789.8 (up 59.04% YoY) and the FY2021 annual result came in at $2.2 million, up 2219.69% from the prior year.
• Gains from Investment Securities eased to -$63220.3 in Q1 2026 per PRQR's latest filing, from $2338.1 in the prior quarter.
• Over five years, Gains from Investment Securities peaked at $117723.8 in Q2 2025 and troughed at -$4.2 million in Q1 2022.
• A 5-year average of -$454722.9 and a median of -$127365.1 in 2023 frame the typical range for Gains from Investment Securities.
• The sharpest annual moves came in 2023 and 2025: Gains from Investment Securities plunged 2426.4% in 2023, then jumped 156.06% in 2025.
• Over 5 years, Gains from Investment Securities stood at -$5041.4 in 2022, then slumped by 2426.4% to -$127365.1 in 2023, then decreased by 19.85% to -$152652.5 in 2024, then jumped by 101.53% to $2338.1 in 2025, then tumbled by 2803.9% to -$63220.3 in 2026.
• According to Business Quant data, Gains from Investment Securities over the past three periods registered -$63220.3, $2338.1, and $117723.8 for Q1 2026, Q3 2025, and Q2 2025 respectively.